Marc Besman

EcoHealth Alliance, Inc. operates a not for profit organization. It protects the health of people, animals, and the environment. Its programs include rift valley fever, predict, health and policy initiatives, monitoring the deadly Nipah virus, emerging disease hotspots, project deep forest, ecohealthy pets, global wildlife trade, and economics of emerging infectious diseases. The company is headquartered in New York, NY.

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

Agenovir Corp. provides research and developing novel antiviral therapeutics for diseases. The company was founded by Bruce Hironaka and Stephen R. Quake and is headquartered in San Francisco, CA.

Aptus Endosystems, Inc. develops and manufactures medical equipment. It focuses on developing technologies to transform Endovascular Aneurysm Repair (EVAR), empowering physicians to perform minimally invasive aneurysm repair while still providing the control and potential long term durability of open surgical repair. The company was founded by Alan Kaganov and Lee Bolduc on August 7, 2002 and is headquartered in Sunnyvale, CA.

Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA.

Bend Research, Inc. provides drug delivery and formulation development technologies. The company is headquartered in Bend, OR.

Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA.

TRIA Beauty, Inc. provides light based therapeutic beauty devices. It offers TRIA Laser Hair Removal System for laser removal of hair and TRIA Skin Perfecting Blue Light for mild to moderate inflammatory acne with a proprietary cleanser and serum for overall complexion improvement. The company was founded in 2003 by Tobin C. Island, Robert E. Grove, Jonathon T. Pearson and Mark V. Weckwerth and is headquartered in Dublin, CA.

Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors.

FLG Partners LLC is a CFO solutions, CEO, and board advisory services provider based in Silicon Valley. The private company is based in Palo Alto, CA, and has subsidiaries in the United States. The company offers financial and operational leadership to a wide range of companies, from newly funded startups to Fortune 100 companies, across various sectors, including technology, life sciences, and consumer products. The firm's partners engage clients in interim or long-term assignments in leadership roles that typically are consulting engagements. FLG Partners has helped raise over $6 billion in growth financing, IPO, and M&A transactions for the firm's clients since January 2021. The company was founded by Douglas J. Lehrmann, Jeffrey S. Kuhn, Kyle W. Smith.

Levitasbio, Inc. provides redefining cellular analytics with its novel platform magnetic levitation technology. The company was founded by Utkan Demirci, Lars Steinmetz and Gozde Durmus and is headquartered in Menlo Park, CA.

Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company based in Cambridge, MA. The company is focused on creating cellular medicines to reverse devastating diseases such as neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock Therapeutics's lead clinical program, Bemdaneprocel, is in phase I clinical trials for Parkinson's disease. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. The company was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation.